These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 37247499)
21. Machine learning-based disulfidptosis-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity in hepatocellular carcinoma. Pu L; Sun Y; Pu C; Zhang X; Wang D; Liu X; Guo P; Wang B; Xue L; Sun P Sci Rep; 2024 Feb; 14(1):4354. PubMed ID: 38388539 [TBL] [Abstract][Full Text] [Related]
22. Unveiling the hidden role of disulfidptosis in kidney renal clear cell carcinoma: a prognostic signature for personalized treatment. Ye Y; Zeng S; Hu X Apoptosis; 2024 Jun; 29(5-6):693-708. PubMed ID: 38296888 [TBL] [Abstract][Full Text] [Related]
23. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma. Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642 [TBL] [Abstract][Full Text] [Related]
24. Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer. Liang J; Wang X; Yang J; Sun P; Sun J; Cheng S; Liu J; Ren Z; Ren M Front Immunol; 2023; 14():1198826. PubMed ID: 38035071 [TBL] [Abstract][Full Text] [Related]
25. Disulfidptosis-related lncRNA signatures assess immune microenvironment and drug sensitivity in hepatocellular carcinoma. Xu K; Dai C; Yang J; Xu J; Xia C; Li J; Zhang C; Xu N; Wu T Comput Biol Med; 2024 Feb; 169():107930. PubMed ID: 38199215 [TBL] [Abstract][Full Text] [Related]
26. Identification of disulfidptosis-related genes with immune infiltration in hepatocellular carcinoma. Li XM; Liu SP; Li Y; Cai XM; Zhang SB; Xie ZF Heliyon; 2023 Aug; 9(8):e18436. PubMed ID: 37520990 [TBL] [Abstract][Full Text] [Related]
27. Based on disulfidptosis-related glycolytic genes to construct a signature for predicting prognosis and immune infiltration analysis of hepatocellular carcinoma. Wang Z; Chen X; Zhang J; Chen X; Peng J; Huang W Front Immunol; 2023; 14():1204338. PubMed ID: 37680641 [TBL] [Abstract][Full Text] [Related]
28. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer. Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G Front Genet; 2022; 13():919389. PubMed ID: 35783281 [No Abstract] [Full Text] [Related]
29. Development and validation of a disulfidptosis-related scoring system to predict clinical outcome and immunotherapy response in acute myeloid leukemia by integrated analysis of single-cell and bulk RNA-sequencing. Zhong F; Jiang J; Yao FY; Liu J; Shuai X; Wang XL; Huang B; Wang X Front Pharmacol; 2023; 14():1272701. PubMed ID: 38053840 [No Abstract] [Full Text] [Related]
30. Identification of disulfidptosis-related subtypes and development of a prognosis model based on stacking framework in renal clear cell carcinoma. Peng K; Wang N; Liu Q; Wang L; Duan X; Xie G; Li J; Ding D J Cancer Res Clin Oncol; 2023 Nov; 149(15):13793-13810. PubMed ID: 37530800 [TBL] [Abstract][Full Text] [Related]
31. Correlation analysis of disulfidptosis-related gene signatures with clinical prognosis and immunotherapy response in sarcoma. Xu J; Guo K; Sheng X; Huang Y; Wang X; Dong J; Qin H; Wang C Sci Rep; 2024 Mar; 14(1):7158. PubMed ID: 38531930 [TBL] [Abstract][Full Text] [Related]
32. Role of disulfidptosis in colorectal adenocarcinoma: implications for prognosis and immunity. Yang R; Lai C; Huang L; Li F; Peng W; Wu M; Xin J; Lu Y; Ouyang M; Bai Y; Lei H; He S; Lin Y Front Immunol; 2024; 15():1409149. PubMed ID: 39399504 [TBL] [Abstract][Full Text] [Related]
33. Signature Construction and Disulfidptosis-Related Molecular Cluster Identification for Better Prediction of Prognosis in Glioma. Zhuang Y; Chen J; Mai Z; Huang W; Zhong W J Mol Neurosci; 2024 Apr; 74(2):38. PubMed ID: 38573391 [TBL] [Abstract][Full Text] [Related]
34. Development of the RF-GSEA Method for Identifying Disulfidptosis-Related Genes and Application in Hepatocellular Carcinoma. Ni L; Yu Q; You R; Chen C; Peng B Curr Issues Mol Biol; 2023 Nov; 45(12):9450-9470. PubMed ID: 38132439 [TBL] [Abstract][Full Text] [Related]
35. Disulfidptosis-Associated lncRNAs are Potential Biomarkers for Predicting Immune Response and Prognosis Within Individuals Diagnosed with Hepatocellular Carcinoma. Wei Q; Hou YC; Mao FF; Feng JK; Wang X; Cheng SQ Hepat Med; 2023; 15():249-264. PubMed ID: 38162389 [TBL] [Abstract][Full Text] [Related]
36. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma. Liu R; Liu Y; Zhang F; Wei J; Wu L Front Immunol; 2023; 14():1146411. PubMed ID: 37063920 [TBL] [Abstract][Full Text] [Related]
37. A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma. Zhang HB; Pan JY; Zhu T Front Pharmacol; 2023; 14():1254119. PubMed ID: 37822882 [No Abstract] [Full Text] [Related]
38. Identification and validation of immunity- and disulfidptosis-related genes signature for predicting prognosis in ovarian cancer. Jin M; Ni D; Cai J; Yang J Heliyon; 2024 Jun; 10(12):e32273. PubMed ID: 38952356 [TBL] [Abstract][Full Text] [Related]
39. A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility. Liu Y; Meng J; Ruan X; Wei F; Zhang F; Qin X Sci Rep; 2024 Jan; 14(1):746. PubMed ID: 38185671 [TBL] [Abstract][Full Text] [Related]
40. Identifying disulfidptosis subtypes in hepatocellular carcinoma through machine learning and preliminary exploration of its connection with immunotherapy. Chen G; Zhang G; Zhu Y; Wu A; Fang J; Yin Z; Chen H; Cao K Cancer Cell Int; 2024 Jun; 24(1):194. PubMed ID: 38831301 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]